title: Rasburicase for the management of tumor lysis syndrome in neonates.
abstract: OBJECTIVE
  To describe the management of tumor lysis syndrome (TLS) with rasburicase in 2 patients who presented with cancer within the first month of life and compare and contrast both cases with respect to their underlying renal physiology, management, and eventual outcome.
  
  
  METHODS
  TLS developed in 2 neonates born at 38 weeks' gestational age; both were managed in part with rasburicase. One patient was a 21-day-old infant who received 2 days of induction chemotherapy for the treatment of congenital Stage IV-S neuroblastoma. With a single 0.2 mg/kg dose of rasburicase, the serum urate level normalized and the infant completed therapy without incident. The second patient was a 4-day-old neonate with congenital precursor-B cell acute lymphoblastic leukemia who presented with spontaneous TLS complicated by renal dysfunction. Despite several doses of intravenous rasburicase (2 doses of 0.1 mg/kg and 4 doses of 0.2 mg/kg), as well as aggressive supportive therapy, the infant died of complications arising from uncontrolled TLS.
  
  
  CONCLUSIONS
  Neonates may be at particular risk for TLS given their immature renal function and its predisposition toward metabolic derangements. While rasburicase has the potential to provide a rapid reversal of TLS in this patient population, when TLS is complicated by pre-existing acute renal failure, additional interventions and alternative anti-tumor strategies may be necessary for a successful outcome. When managing TLS in infancy, clinicians must consider the relative degree of renal immaturity and its predisposition toward metabolic derangements.
  
  
  CONCLUSIONS
  Rasburicase appears to be well tolerated and effective in lowering serum urate concentrations in the treatment of therapy-related TLS in neonates. However, in instances of spontaneous TLS complicated by the normally low glomerular filtration rate in the newborn infant, the use of rasburicase and other supportive care measures may still be inadequate, warranting further study.
authors.affiliation: University of Maryland, Baltimore, USA.
authors.forename: Deborah M
authors.initials: DM
authors.lastname: McNutt
authors.forename: Mark T
authors.initials: MT
authors.lastname: Holdsworth
authors.forename: Craig
authors.initials: C
authors.lastname: Wong
authors.forename: Jeffery D
authors.initials: JD
authors.lastname: Hanrahan
authors.forename: Stuart S
authors.initials: SS
authors.lastname: Winter
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000097:blood / Q000150:complications / Q000151:congenital / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009447:Neuroblastoma / Q000097:blood / Q000150:complications / Q000151:congenital / Q000188:drug therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000150:complications / Q000188:drug therapy; D015275:Tumor Lysis Syndrome / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D014503:Urate Oxidase / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; C469709:rasburicase; D014527:Uric Acid; D014503:Urate Oxidase